Menu

EPA Seeks to Restrict the Science Used in Policymaking

Republican politicians have been trying to limit data to only those publicly available, but opponents say that would neglect private, yet important, information.

Apr 23, 2018
Kerry Grens

ISTOCK, DRNADIGEmailed correspondence between the offices of Congressman Lamar Smith (R-TX) and Environmental Protection Agency (EPA) Administrator Scott Pruitt reveal a partnership to enact a proposal Smith has been trying to get into law. The initiative would limit the data used in making environmental policies to only those that are publicly available.

Supporters say the data restriction is intended to boost transparency at the agency, while opponents are concerned that certain studies—such as public health research that includes sensitive information—would be tossed out when crafting policies.

“This idea to restrict the use of science at EPA was hatched solely and worked on almost exclusively by political appointees who are doing everything they can to ensure that independent science doesn’t get in the way of policy decisions at the agency,” Union of Concerned Scientists (UCS) spokesman Yogin Kothari tells E&E News. “It’s an effort to stack the deck in favor of industry that EPA is supposed to regulate.”

The policy is based on the so-called HONEST Act, passed by the US House of Representatives last year, but not yet considered by the Senate. “If we use a third party to engage in scientific review or inquiry, and that’s the basis of rulemaking, you and every American citizen across the country deserve to know what’s the data, what’s the methodology that was used to reach that conclusion that was the underpinning of what—rules that were adopted by this agency,” Pruitt told the Daily Caller News Foundation in March.

See “House Votes to Limit EPA Decision Making

The collaboration between Smith and EPA was made public by Freedom of Information Act requests filed by UCS. In January, the documents show, Pruitt and Smith had a meeting, and in February, an email from a member of EPA’s policy office declared that Pruitt’s chief of staff “asked to have this [program] rolled out by the end of the month,” according to E&E News.

The policy could have wide-reaching effects, according to an EPA official who expressed concerns about data restriction. “The directive needs to be revised,” Nancy Beck, deputy assistant administrator in the EPA’s chemicals office, wrote to her colleagues, according to The Hill. “Without changes it will jeopardize our entire pesticide registration/re-registration review process and likely all [Toxic Substances Control Act] risk evaluations.” Of concern, she explained, is that companies will contribute “extremely valuable, extremely high quality” study findings to be used in policy decisions that do not get published.

It’s not clear if the policy is yet in effect. “These discussions are part of the deliberative process; the policy is still being developed,” EPA spokeswoman Liz Bowman tells The Hill.

See “Scott Pruitt’s Questionable Practices Exposed

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.